About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Home Based Phototherapy for Neonatal Jaundice

Clinicaltrials.gov identifier NCT03933423

Recruitment Status Recruiting

First Posted May 1, 2019

Last update posted February 18, 2021

Study Description

Brief summary:

The main purpose of the study is to deliver community health worker based prevention, early screening and management of neonatal Jaundice using battery powered LED phototherapy device at the household level.

  • Condition or Disease:Neonatal Jaundice
  • Intervention/Treatment: Device: Home based phototherapy and referral
  • Phase: N/A
Detailed Description

Bangladesh like other low and middle-income countries has a high burden of hyperbilirubinemia induced neonatal morbidity and mortality. Approximately 60%-80% of newborns develop neonatal jaundice and 18% of infants are at risk for adverse outcomes from neonatal jaundice. Severe neonatal jaundice can put neonates at risk for long term neuro-developmental impairments and death. Delay in diagnosis and treatment of severe neonatal jaundice can result in brain damage to the newborn that is preventable with timely treatment. Approximately 14 million infants per year in low to middle-income countries (LMIC) are at risk from neonatal jaundice progressing to extreme hyperbilirubinemia and brain damage. Nearly 80% of the 481,000 cases of extreme hyperbilirubinemia are in LMIC because infants are identified too late or health facility treatment is inaccessible or inadequate. New, low-cost, easy to use screening and phototherapy treatment technologies enable our proposed redesign of care delivery in LMIC to save infant's brains. The investigators plan to shift care from specialists and hospitals to community health workers (CHW) and homes. Investigators will integrate CHW-led prevention during pregnancy, with timely household screening and treatment. Investigators will reach infants before brain damage occurs and treat infants who would not otherwise be treated. LMIC including Bangladesh have had difficulty addressing neonatal jaundice because of the expense and logistics of providing timely prevention, screening and treatment to families. This study aim to test 3 hypothesis: H1: Prenatal modules for pregnant mothers will increase breastfeeding rates at 1 hour of life and at 3 months of age. H2: CHWs can screen 80% of newborns by 48 hours of age for jaundice and are skilled in identifying sick infants. H3: CHW-led household screening for neonatal jaundice will increase the rate of indicated treatment for neonatal jaundice compared to current practice. Investigators will conduct formative research to engage Government and other stakeholders to develop intervention package for prevention and treatment of neonatal jaundice and configuring and adapting LED phototherapy device to use for home treatment. Investigators will then conduct randomized control trial to implement the intervention package in intervention community and will assess the effectiveness of the intervention package. Investigators will compare the rates of indicated treatment for neonatal jaundice in the intervention and treatment arms.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 500 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Using Community Health Workers and In-home LED Phototherapy to Dramatically Reduce Brain Damage From Neonatal Jaundice in Low to Middle Income Countries: A Feasibility Trial
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: June 2021
  • Estimated Study Completion Date: June 2021
Arms and interventions
Arm Intervention/treatment
Active Comparator: Intervention
Educational session of pregnant mothers, blood grouping of parents and identifying risk factors for developing jaundice, screening newborns for neonatal jaundice, glucose 6-phosphate dehydrogenase deficiency and illness, Home based phototherapy and referral.
Device: Home based phototherapy and referral
CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
Outcome Measures
  • Primary Outcome Measures: 1. Breastfeeding rates within 1 hour of age [ Time Frame: 6-8 months after the intervention ]
    Mother reported breastfeeding rates within 1 hour of age will be measured following structured survey
  • 2. Breastfeeding rates upto 3 months of age [ Time Frame: 6-8 months after the intervention ]
    Mother reported breastfeeding rates after 3 months of age will be measured following structured survey
  • 3. Number of newborns having at least one postnatal check-up within 48 hours. [ Time Frame: 6-8 months after the intervention ]
    This measurement will be taken within 2 months of child birth through a structured survey, reported by mother.
  • 4. Number of newborns screened for neonatal jaundice [ Time Frame: 6-8 months after the intervention ]
    Number of newborns screened for neonatal jaundice either in home or any government or non-government health facilities within 7 days of birth through a structured survey reported by mother.
  • 5. Number of newborns that received indicated treatment for neonatal jaundice [ Time Frame: 6-8 months after the intervention ]
    Number of children receiving indicated treatment for neonatal jaundice either in home or health facilities will be measured by a mother reported structured survey after 2 months of child birth
  • 6. Community health workers (CHW's) skill in assessing sick newborns [ Time Frame: During 6-8 months of the intervention ]
    CHW's skill will be measured through a structured observation following a check list and subjective and objective assessment by registered physician
Eligibility Criteria
  • Ages Eligible for Study: 18 to 45 Years (Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: Yes

Inclusion Criteria:

- The mothers are at late 2nd or early 3rd trimester of their pregnancy and agreed to
enroll as study participants

- They are planning to stay in the study village for the next 12 months (if a mother is
planning to give birth at her natal home and then return, she will still not be a
candidate for enrollment)

Exclusion Criteria:

- Pregnant mother with confirmed multiple pregnancy.

- Pregnant mother with medically identified psychological disorder.

- Any known maternal danger sign.

Contacts and Locations

Contact: Md Mahbubur Rahman, MBBS 8802-9827001 ext 4003 mahbubr@icddrb.org


Bangladesh, Dhaka

Sponsors and Collaborators

International Centre for Diarrhoeal Disease Research, Bangladesh

Stanford University

Dhaka Shishu Hospital

More Information
  • Responsible Party: International Centre for Diarrhoeal Disease Research, Bangladesh
  • ClinicalTrials.gov Identifier: NCT03933423 History of Changes
  • Other Study ID Numbers: PR-19004
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: February 18, 2021
  • Last Verified: April 2020
  • Individual Participant
    Data (IPD) Sharing
  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Jaundice, Neonatal Jaundice